Exploring environmental causes of altered ras effects: Fragmentation plus integration?

Molecular Carcinogenesis

Volumn 36, Issue 2, 2003, Pages 45-52

  Porta, Miquel ^a,b   Ayude, Daniel ^a,b   Alguacil, Juan ^a,c   Jariod, Manuel ^a  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Environment chemistry; Mutation spectra; Neoplasms; Organic chemicals; Pancreas; Ras genes

Indexed keywords

ASBESTOS; CAFFEINE; MUTAGENIC AGENT; ORGANIC COMPOUND; ORGANIC SOLVENT; ORGANOCHLORINE DERIVATIVE;

APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CHEMISTRY; COFFEE; COLON CANCER; DIET; DNA REPAIR; ENVIRONMENTAL FACTOR; ENZYME INDUCTION; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENOTOXICITY; HUMAN; LUNG CANCER; NEOPLASM; NONHUMAN; ONCOGENE RAS; PANCREAS CANCER; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; REVIEW;

COFFEE; GENES, RAS; HAZARDOUS SUBSTANCES; HUMANS; HYDROCARBONS, CHLORINATED; MUTATION; PANCREATIC NEOPLASMS; RISK FACTORS;

EID: 0037312597     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10093     Document Type: Review

References (127)

1. Feig LA, Urano T, Cantor S. Evidence for a Ras/Ral signaling cascade. Trends Biochem Sci 1996;21:438-441.
2. Katz ME, McCormick F. Signal transduction from multiple Ras effectors. Curr Opin Genet Dev 1997;7:75-79.
3. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998;8:49-54.
4. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998;10:262-267.
5. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of ras signaling. Oncogene 1998;17:1395-1413.
6. Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ. Rho family proteins and Ras transformation: RHOad less traveled gets congested. Oncogene 1998;17:1415-1438.
7. Wolthius RM, Bos JL. Ras caught in another affair: The exchange factors for Ral. Curr Opin Genet Dev 1999;9:112-117.
8. Magee T, Marshall C. New insights into the interaction of Ras with the plasma membrane. Cell 1999;98:9-12.
9. Marshall C. How do small GTPase signal transduction pathways regulate cell cycle entry? Curr Opin Cell Biol 1999;11:732-736.
10. Shields JM, Pruitt K, McFall A, Shaub A, Der C. Understanding Ras: "It ain't over 'til its over." Trends Cell Biol 2000;10:147-154.
11. Ruddon RW. Cancer biology, 3rd edition. New York: Oxford University Press; 1995. p 288-291.
12. Cooper GM. Oncogenes, 2nd edition. Boston: Jones and Bartlett; 1995. p 169-173, 257.
13. Bos JL. The ras gene family and human carcinogenesis. Mutat Res 1988;195:225-271.
14. Gress TM, editor. Molecular pathogenesis of pancreatic cancer. Amsterdam: IOS Press; 2000. Available from: http://www.lif.icnet.uk/axp/mphh/biomed/[last accessed 15 May 2002]
15. Biankin AV, Kench JG, Morey AL, et al. Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 2001;61:8830-8837.
16. Real FX. The cell biology of pancreatic cancer. In: Neoptolemos J, Lemoine NR, editors. Pancreatic cancer: Molecular and clinical advances. London: Blackwell; 1995. p 3-17.
17. McCormick CSF, Lemoine NR. Molecular biology: Diagnostic and therapeutic potentials. In: Howard JM, Idezuki Y, Ihse I, Prinz RA, editors. Surgical diseases of the pancreas, 3rd. edition Baltimore: Williams and Wilkins; 1998. p 439-448.
18. Goggins M, Offerhaus GJ, Hilgers W, et al. Pancreatic carcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Am J Pathol 1998;152:1501-1507.
19. Malats N, Porta M, Corominas JM, Pinol JL, Rifa J, Real FX. Ki-ras mutations in exocrine pancreatic cancer: Association with clinico-pathological characteristics, and with tobacco and alcohol consumption. Int J Cancer 1997;70:661-667.
20. Weiderpass E, Partanen T, Kaaks R, et al. Occurrence, trends and environmental etiology of pancreatic cancer. Scand J Work Environ Health 1998;24:165-174.
21. Anderson KE, Potter JD, Mack TM. Pancreatic cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention, 2nd. edition. New York: Oxford University Press; 1996. p 725-771.
22. Porta M, Malats N, Jariod M, et al. Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. Lancet 1999;354:2125-2129.
23. Porta M, Jariod M, Malats N, et al. Prevalence of K-ras mutations at diagnosis and serum levels of DDT, DDE, PCBs and other organochlorine compounds in exocrine pancreatic cancer. In: Gress TM, editor. Molecular pathogenesis of pancreatic cancer. Amsterdam: IOS Press; 2000. p 37-44. Available from: http://www.lif.icnet.uk/axp/mphh/biomed/porta.html [last accessed 24 Sept. 2002].
24. Hansen LG. Stepping backward to improve assessment of PCB congener toxicities. Environ Health Perspect 1998;106(suppl 1):171-189.
25. Porta M, Zumeta E. Implementing the Stockholm treaty on POPs [Editorial]. Occup Environ Med 2002;59:651-652.
26. Longnecker MP, Rogan WJ, Lucier G. The human health effects of DDT (dichlorodiphenyl-trichloroethane) and PCBs (polychlorinated biphenyls) and an overview of organochlorines in public health. Annu Rev Publ Health 1997;18:211-244.
27. Porta M, Ruiz L, Jariod M, et al. Correlations among serum concentrations of highly prevalent organochlorine compounds in patients with exocrine pancreatic cancer. Organohalogen Compounds 2002;55:307-310.
28. Porta M, Zumeta E, Ruiz L, et al. The influence of age and gender on serum concentrations of p,p′DDT, p,p′DDE and the DDT/DDE ratio in subjects with exocrine pancretic cancer. Organohalogen Compounds 2002;59:351-354.
29. Alguacil J, Porta M, Malats N, et al. Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer. Carcinogenesis 2002;23:101-106.
30. Porta M, Malats N, Guarner L, et al. Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. J Epidemiol Commun Health 1999;53:702-709.
31. Porta M, Malats N, Alguacil J, et al. Coffee, pancreatic cancer, and K-ras mutations: Updating the research agenda. J Epidemiol Commun Health 2000;54:656-659.
32. Vineis P. ras mutations and a cup of coffee: Cause, confounder, effect modifier, or what else? [Editorial]. J Epidemiol Commun Health 1999;53:685.
33. Abdulla S. Science update: Mocha and mutations. Nature 1999; [on-line] December 15. Available from: http://www.nature.com/nsu/991216/991216-9.html [last accessed 24 Sept. 2002].
34. Kuper HE, Mucci LA, Trichopoulos D. Coffee, pancreas cancer and the question of causation. J Epidemiol Commun Health 2000;54:650-651.
35. Slebos RJC, Hoppin JA, Tolbert PE, et al. K-ras and p53 in pancreatic cancer: Association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol Biomark Prev 2000;9:1223-1232.
36. Hoppin JA, Tolbert PE, Holly EA, et al. Pancreatic cancer and serum organochlorine levels. Cancer Epidemiol Biomark Prev 2000;9:199-205.
37. Garabrant DH, Held J, Homa D. DDT and pancreatic cancer: Response to Malats et al. J Natl Cancer Inst 1993;85:328-329.
38. Ojajarvi IA, Partanen TJ, Ahlbom A, et al. Risk of pancreatic cancer in workers exposed to chlorinated hydrocarbon solvents and related compounds: A meta-analysis. Am J Epidemiol 2001;153:841-850.
39. Stolzenberg-Solomon RZ, Pietinen P, Taylor PR, Virtamo J, Albanes D. Prospective study of diet and pancreatic cancer in male smokers. Am J Epidemiol 2002;155:783-792.
40. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 53: Occupational exposures in insecticide application, and some pesticides. Lyon: International Agency for Research on Cancer; 1991.
41. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Overall evaluations of carcinogenicity: An updating of IARC monographs volumes 1-42. Suppl. 7. Lyon: International Agency for Research on Cancer; 1987. p 186-189, 322-326.
42. Cogliano VJ. Assessing the cancer risk from environmental PCBs. Environ Health Perspect 1998;106:317-323.
43. Chan PC, Huff J, Haseman JK, Alison R, Prejean JD. Carcinogenesis studies of dichlorvos in Fischer rats and B6C3F1 mice. Jpn J Cancer Res 1991;82:157-164.
44. Kaiser J. Endocrine disrupters: Panel cautiously confirms low-dose effects. Science 2000;290:695-697.
45. Kaiser J. Hazards of particles, PCBs focus of Philadelphia meeting. Science 2000;288:424-425.
46. Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA, Wilson EM. Persistent DDT metabolite p,p′-DDE is a potent androgen receptor agonist. Nature 1995;375:581-585.
47. Wolff MS, Toniolo PG. Environmental organochlorine exposure as a potential etiologic factor in breast cancer. Environ Health Perspect 1995;103(suppl 7):141-145.
48. McKinney JD, Waller CL. Polychlorinated biphenyls as hormonally active structural analogues. Environ Health Perspect 1994;102:290-297.
49. Longnecker DS. Experimental models of exocrine pancreatic tumors. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, editors. The pancreas: Biology, pathobiology, and disease, 2nd. edition. New York: Raven; 1993. p 551-564.
50. Watanapa P, Williamson RCN. Experimental pancreatic hyperplasia and neoplasia: Effects of dietary and surgical manipulation. Br J Cancer 1993;67:877-884.
51. Longnecker DS. Hormones and pancreatic cancer. Int J Pancreatol 1991;9:81-86.
52. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203-232.
53. Scheele GA. Regulation of pancreatic gene expression in response to hormonal and nutritional substrates. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, editors. The pancreas: Biology, pathobiology, and disease, 2nd. edition. New York: Raven Press; 1993. p 103-120.
54. Lu D, Giguere V. Requirement of Ras-dependent pathways for activation of the transforming growth factor beta3 promoter by estradiol. Endocrinology 2001;142:751-759.
55. DeVivo I, Marion MJ, Smith SJ, Carney WP, Brandt-Rauf PW. Mutant c-Ki-ras protein in chemical carcinogenesis in humans exposed to vinyl chloride. Cancer Causes Control 1994;5:273-278.
56. Li D. Molecular epidemiology of pancreatic cancer. Cancer J 2001;7:259-265.
57. Li D, Firozi PF, Zhang W, et al. DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. Mutat Res 2002;513:37-48.
58. Gribaldo L, Sacco MG, Casati S, et al. Modulation of protooncogene expression by polychlorinated biphenyls in 3T3-L1 cell line. J Toxicol Environ Health 1998;55(A):121-131.
59. Hornhardt S, Jenke HS, Michel G. Polychlorinated biphenyls modulate protooncogene expression in Chang liver cells. FEBS Lett 1994;339:185-188.
60. Oakley GG, Devanaboyina U, Robertson LW, Gupta RC. Oxidative DNA damage induced by activation of polychlorinated biphenyls (PCBs): Implications for PCB-induced oxidative stress in breast cancer. Chem Res Toxicol 1996;9:1285-1292.
61. Choi CH, Kim HS, Kweon OS, et al. Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines. Mol Cells 2000;10:38-46.
62. Tsukamoto M, Tampo Y, Sawada M, Yonaha M. Paraquat-induced oxidative stress and dysfunction of the glutathione redox cycle in pulmonary microvascular endothelial cells. Toxicol Appl Pharmacol 2002;178:82-92.
63. Service RF. New role for estrogen in cancer? Science 1998;279:1631-1633.
64. Turusov V, Rakitsky V, Tomatis L. Dichlorodiphenyltrichloroethane (DDT): Ubiquity, persistence and risks. Environ Health Perspect 2002;110:125-128.
65. Chuang LF, Chuang RY. The effect of heptachlor on ras proto-oncogene expression in human myeloblastic leukemia (ML-1) cells. Toxicology 1991;70:283-292.
66. Suzuki H, Suzuki N. Piperonyl butoxide mutagenicity in human RSa cells. Mutat Res 1995;344:27-30.
67. Takahashi S, Chi XJ, Yamaguchi Y, et al. Mutagenicity of bisphenol A and its suppression by interferon-alpha in human RSa cells. Mutat Res 2001;490:199-207.
68. Watson MA, Devereux TR, Malarkey DE, Anderson MW, Maronpot RR. H-ras oncogene mutation spectra in B6C3F1 and C 57BL/6 mouse liver tumors provide evidence for TCDD promotion of spontaneous and vinyl carbamate-initiated liver cells. Carcinogenesis 1995;16:1705-1710.
69. Kim TW, Smart RC. Lack of effect of retinoic acid and fluocinolone acetonide on mirex tumor promotion indicates a novel mirex mechanism. Carcinogenesis 1995;16:2199-2204.
70. Vineis P, Malats N, Porta M, Real FX. Human cancer, carcinogenic exposures and mutational spectra. Mutat Res 1999;436:185-194.
71. Wölfle D. Interactions between 2,3,7,8-TCDD and PCBs as tumor promoters: Limitations of TEFs. Teratogenesis Carcinog Mutagen 1998;17:217-224.
72. Li HC, Dehal SS, Kupfer D. Induction of the hepatic CYP2B and CYP3A enzymes by the proestrogenic pesticide methoxychlor and by DDT in the rat: Effects on methoxychlor metabolism. J Biochem Toxicol 1995;10:51-61.
73. Wolff MS, Camann D, Gammon M, Stellman SD. Proposed PCB congener groupings for epidemiological studies. Environ Health Perspect 1997;105:13-14.
74. Williams GT. Programmed cell death: Apoptosis and oncogenesis. Cell 1991;65:1097-1098.
75. Mayo MW, Wang CY, Cogswell PC, et al. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 1997;278:1812-1815.
76. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997;385:544-548.
77. Schulze A, Lehmann K, Jefferies HB, McMahon M, Downward J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev 2001;15:981-994.
78. Chuang LF, Chuang RY. Heptachlor and the mitogen-activated protein kinase module in human lymphocytes. Toxicology 1998;128:17-23.
79. Davis JW 2nd, Lauer FT, Burdick AD, Hudson LG, Burchiel SW. Prevention of apoptosis by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the MCF-10A cell line: Correlation with increased transforming growth factor alpha production. Cancer Res 2001;61:3314-3320.
80. Ramakrishna G, Perella C, Birely L, Diwan BA, Fornwald LW, Anderson LM. Decrease in K-ras p21 and increase in Raf1 and activated Erk 1 and 2 in murine lung tumors initiated by N-nitrosodimethylamine and promoted by 2,3,7,8-tetra-chlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 2002;179:21-34.
81. Ramakrishna G, Anderson LM. Levels and membrane localization of the c-K-ras p21 protein in lungs of mice of different genetic strains and effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and Aroclor 1254. Carcinogenesis 1998;19:463-470.
82. Irani K, Xia Y, Zweier JL, et al. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 1997;275:1649-1652.
83. Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS Jr. Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem 1997;272:24113-24116.
84. Baichwal VR, Baeuerle PA. Activate NF-kappa B or die? Curr Biol 1997;7:R94-R96.
85. Marion MJ, Froment O, Trepo C. Activation of Ki-ras gene by point mutation in human liver angiosarcoma associated with vinyl chlorid exposure. Mol Carcinog 1991;4:450-454.
86. Taylor JA, Sandler DP, Bloomfield CD, et al. Ras oncogen activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst 1992;84:1626-1632.
87. Zhuang SM, Cochran C, Goodrow T, Wiseman RW, Soderkvist P. Genetic alterations of p53 and ras genes in 1,3-butadiene and 2′,3′-dideoxycitidine-induced lymphomas. Cancer Res 1997;57:2710-2714.
88. Marion MJ, Boivin-Angele S. Vinyl chloride-specific mutations in humans and animals. IARC Sci Publ 1999;150:315-324.
89. Boivin-Angele S, Lefrancois L, Froment O, et al. Ras gene mutations in vinyl chloride-induced liver tumours are carcinogen-specific but vary with cell type and species. Int J Cancer 2000;85:223-227.
90. Barbin A. Etheno-adduct-forming chemicals: From mutagenicity testing to tumor mutation spectra. Mutat Res 2000;462:55-69.
91. Kielhorn J, Melber C, Wahnschaffe U, Aitio A, Mangelsdorf I. Vinyl chloride: Still a cause for concern. Environ Health Perspect 2000;108:579-588.
92. Motohashi N, Nagashima H, Molnar J. Trichloroethylene. II. Mechanism of carcinogenicity of trichloroethylene. In Vivo 1999;13:215-219.
93. Luo JC, Liu HT, Cheng TJ, Du CL, Wang JD. Plasma Asp13-ki-ras oncoprotein expression in vinyl chloride monomer workers in Taiwan. J Occup Environ Med 1998;40:1053-1058.
94. Anderson D, Hughes JA, Brinkworth MH, Peltonen K, Sorsa M. Levels of ras oncoproteins in human plasma from 1,3-butadiene-exposed workers and controls. Mutat Res 1996;349:115-120.
95. Anderson D, Hughes JA, Veidebaum T, Peltonen K, Sorsa M. Examination of ras (p21) proteins in plasma from workers exposed to benzene emissions from petrochemical plants and healthy controls. Mutat Res 1997;381:149-155.
96. Anderson D, Hughes JA, Brinkworth MH, et al. Examination of ras oncoproteins in human plasma from healthy controls and workers exposed to petroleum emissions, including benzene-related compounds. Mutat Res 1999;445:167-173.
97. Nakayama A, Koyoshi S, Morisawa S, Yagi T. Comparison of the mutations induced by p-benzoquinone, a benzene metabolite, in human and mouse cells. Mutat Res 2000;470:147-153.
98. Vodicka P, Tvrdik T, Osterman-Golkar S, et al. An evaluation of styren genotoxicity using several biomarkers in a 3-year follow-up study of hand-lamination workers. Mutat Res 1999;445:205-224.
99. Jansen JG, Vrieling H, van Teijlingen CM, Mohn GR, Tates AD, van Zeeland AA. Marked differences in the role of O6-alkylguanine in hprt mutagenesis in T-lymphocytesof rats exposed in vivo to ethylmethanesulfonate, N-(2-hydroxyethyl)-N-nitrosurea, or N-ethyl-N-nitrosurea. Cancer Res 1995;55:1875-1882.
100. Devereux TR, Foley JF, Maronpot RR, Kari F, Anderson MW. Ras proto-oncogene activation in liver and lung tumors from B6C3F1 mice exposed chronically to methylene chloride. Carcinogenesis 1993;14:795-801.
101. Rossi AM, Guarnieri C, Rovesti S, et al. Genetic polymorphisms influence variability in benzene metabolism in humans. Pharmacogenetics 1999;9:445-451.
102. Pavanello S, Clonfero E. Biological indicators of genotoxic risk and metabolic polymorphisms. Mutat Res 2000;463:285-308.
103. Lafuente MJ, Casterad X, Trias M, et al. NAD(P)H: Quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis 2000;21:1813-1819.
104. Porta M, Malats N, Vioque J, et al. Incomplete overlapping of biological, clinical and environmental information in molecular epidemiologic studies: A variety of causes and a cascade of consequences. J Epidemiol Commun Health 2002;56:734-738.
105. Mohr U, Emura M, Riebe-Imre M. Experimental studies on carcinogenity and mutagenicity of caffeine. In: Garattini S, editor. Caffeine, coffee, and health. New York: Raven Press; 1993. p 359-378.
106. Link CJ Jr, Evans MK, Cook JA, Muldoon R, Stevnsner T, Bohr VA. Caffeine inhibits gene-specific repair of UV-induced damage in hamster cells and in human xeroderma pigmentosum group C cells. Carcinogenesis 1995;16:1149-1155.
107. DeFrank JS, Tang W, Powell SN. p53-null cells are more sensitive to ultraviolet light only in the presence of caffeine. Cancer Res 1996;56:5365-5368.
108. Porta M, Ayude D, Vioque J, Alguacil A. Coffee drinking: The rationale for treating it as a potential effect-modifier of carcinogenic exposures. Eur J Epidemiol 2002;18:(in press).
109. Muller WU, Bauch T, Wojcik A, Bocker W, Streffer C. Comet assay studies indicate that caffeine-mediated increase in radiation risk of embryos is due to inhibition of DNA repair. Mutagenesis 1996;11:57-60.
110. Hall-Jackson CA, Cross DA, Morrice N, Smythe C. ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK. Oncogene 1999;18:6707-6713.
111. Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999;59:4375-4382.
112. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814-822.
113. Agapova LS, Ilyinskaya GV, Turovets NA, Ivanov AV, Chumakov PM, Kopnin BP. Chromosome changes caused by alterations of p53 expresion. Mutat Res 1996;354:129-138.
114. Efferth T, Fabry U, Glatte P, Osieka R. Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells. J Cancer Res Clin Oncol 1995;121:648-656.
115. Novell S, Sweeney C, Hammons G, Kadlubar FF, Lang NP. CYP2A6 activity determined by caffeine phenotyping: Association with colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:377-383.
116. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992;2:73-77.
117. Castro GD, Delgado de Layno AM, Costantini MH, Castro JA. Cytosolic xanthine oxidoreductase mediated bioactivation of ethanol to acetaldehyde and free radicals in rat breast tissue: Its potential role in alcohol-promoted mammary cancer. Toxicology 2001;160:11-18.
118. Nelson HH, Christiani DC, Wiencke JK, Mark EJ, Wain JC, Kelsey KT. K-ras mutation and occupational asbestos exposure in lung adenocarcinoma: Asbestos-related cancer without asbestosis. Cancer Res 1999;59:4570-4573.
119. Ahrendt SA, Decker Pa, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001;92:1525-1530.
120. Fujii H, Egami H, Chaney W, Pour P, Pelling J. Pancreatic ductal adenocarcinomas induced in Syrian hamsters by N-nitrosobis(2-oxopropyl)amine contain a c-Ki-ras oncogene with a point-mutated codon 12. Mol Carcinog 1990;3:296-301.
121. Bauer-Hofmann R, Klimek F, Buchmann A, Muller O, Bannasch P, Schwarz M. Role of mutations at codon 61 of the c-Ha-ras gene during diethylnitrosamine-induced hepatocarcinogenesis in C3H/He mice. Mol Carcinog 1992;6:60-67.
122. Kitada H, Tsutsumi M, Tsujiuchi T, et al. Frequent mutations of Ki-ras but no mutations of Ha-ras and p53 in lung lesions induced by N-nitosobis(2-hidroxypropyl)amine in rats. Mol Carcinog 1996;15:276-283.
123. Slattery ML, Curtin K, Anderson K, et al. Associations between dietary intake and Ki-ras mutations in colon tumors: A population-based study. Cancer Res 2000;60:6935-6941.
124. Hughes R, Cross AJ, Pollock JR, Bingham S. Dose-dependent effect of dietary meat on endogenous colonic N-nitrosation. Carcinogenesis 2001;22:199-202.
125. Singh J, Hamid R, Reddy BS. Dietary fat and colon cancer: Modulating effect of types and amount of dietary fat on rasp21 function during promotion and progression stages of colon cancer. Cancer Res 1997;57:253-258.
126. Singh J, Hamid R, Reddy BS. Dietary fish oil inhibits the expression of fanesyl protein transferase and colon tumor development in rodents. Carcinogenesis 1998;19:985-989.
127. Yano T, Uchida M, Yuasa M, Murakami A, Hagiwara K, Ichikawa T. The inhibitory effect of vitamin E on K-ras mutation at an early stage of lung carcinogenesis in mice. Eur J Pharmacol 1997;323:99-102.